Shots:

• The expansion cohort of P-l study involves assessing of mRNA-4157 + Keytruda (pembrolizumab) vs Keytruda monothx. in 10 patients with HPV (-) HNSCC and 17 patients with MSS-CRC- presented at the SITC 2020.
• Results: in the HPV(-) HNSCC group- ORR (50% vs 14.6%) with 2 patients achieving CR & 3 patients achieving PR; mPFS (9.8 vs 2.0 mos.); DCR (90%); median duration of response has not been reached. No responses were observed in the MSS-CRC group of patients
• The company continues to recruit in HPV(-) HNSCC cohort and has decided to expand the size of the current cohort based on the interim data reported

­  Ref: Businesswire | Image: Moderna